medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-14-23-34medsovet-6389Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯARTERIAL HYPERTENSIONПерспективы применения фиксированной комбинации бисопролола и амлодипина в лечении пациентов с постковидным синдромомProspects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndromehttps://orcid.org/0000-0003-0491-8823ПоляковаО. А.PolyakovaO. A.

Полякова Ольга Александровна, врач-терапевт, ассистент кафедры терапии и полиморбидной патологии,

125993, Россия, Москва, ул. Баррикадная, д. 2/1, стр. 1

Olga A. Polyakova, Therapist, Assistant of the Department of Therapy and Polymorbid Pathology

2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993

docpolyakova.olga@gmail.comhttps://orcid.org/0000-0002-0795-8823ОстроумоваО. Д.OstroumovaO. D.

Остроумова Ольга Дмитриевна, д.м.н., профессор, заведующий кафедрой терапии и полиморбидной патологии

125993, Россия, Москва, ул. Баррикадная, д. 2/1, стр. 1

Olga D. Ostroumova, Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology

2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993

ostroumova.olga@mail.ruhttps://orcid.org/0000-0002-2988-1767МироноваЕ. В.MironovaE. V.

Миронова Елена Владимировна, к.м.н., врач-кардиолог, заведующий кардиологическим отделением

125367, Россия, Москва, Волоколамское шоссе, д. 84, стр. 39

Elena V. Mironova, Cand. Sci. (Med.), Cardiologist, Head of the Cardiology Department

84, Bldg. 39, Volokolamskoe Shosse, Moscow, 125367

e.v.mironova@mail.ruhttps://orcid.org/0000-0003-2546-1340ДолдоН. М.DoldoN. M.

Долдо Николай Михайлович, врач-кардиолог, заведующий терапевтическим отделением

125367, Россия, Москва, Волоколамское шоссе, д. 84, стр. 39

Nicolai M. Doldo, Cardiologist, Head of the Therapeutic Department

84, Bldg. 39, Volokolamskoe Shosse, Moscow, 125367

Kolj.spb@mail.ruhttps://orcid.org/0000-0002-0401-1132ЛистратовА. И.ListratovA. I.

Листратов Александр Иванович, ординатор второго года кафедры терапии и полиморбидной патологии

125993, Россия, Москва, ул. Баррикадная, д. 2/1, стр. 1

Alexander I. Listratov, 2nd Year Resident of the Department of Therapy and Polymorbid Pathology

2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993

alexanderlistratoff@yandex.ruhttps://orcid.org/0000-0003-3081-602XФилипповаА. В.FilippovA. V.

Филиппова Анастасия Витальевна, ординатор второго года кафедры терапии и полиморбидной патологии

125993, Россия, Москва, ул. Баррикадная, д. 2/1, стр. 1

Anastasia V. Filippova, 2nd Year Resident of the Department of Therapy and Polymorbid Pathology

2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993

filippova.96@mail.ruРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationЦентральная клиническая больница «РЖД-Медицина»РоссияCentral Clinical Hospital “Russian Railways-Medicine”Russian Federation2021151020210142334Copyright © Полякова О.А., Остроумова О.Д., Миронова Е.В., Долдо Н.М., Листратов А.И., Филиппова А.В., 20212021Полякова О.А., Остроумова О.Д., Миронова Е.В., Долдо Н.М., Листратов А.И., Филиппова А.В.Polyakova O.A., Ostroumova O.D., Mironova E.V., Doldo N.M., Listratov A.I., Filippov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6389

Новая коронавирусная инфекция COVID-19 с момента первого сообщения по настоящее время стремительно распространилась уже более чем в 200 странах по всему миру, создав серьезную угрозу для жизни и здоровья населения. Большинство пациентов, переболевших COVID-19, по-прежнему продолжают предъявлять жалобы на одышку, повышенную утомляемость, боль в груди, сердцебиение и другие симптомы. В настоящее время наличие симптомов через 12 нед. после острой фазы новой коронавирусной инфекции COVID-19  именуется собирательным термином «постковидный синдром». Исследования показали, что этот синдром часто встречается у выздоровевших пациентов с COVID-19 вне зависимости от их возраста и тяжести заболевания. Данная особенность существенно отличает постковидный синдром от других синдромов после перенесенной инфекции, в связи с чем изучение механизмов его развития, способов диагностики и лечения является важной задачей общественного здравоохранения. Особое внимание отводится пациентам с  сопутствующей патологией, в  особенности с гипертонией и сердечно-сосудистыми заболеваниями, так как они имеют более тяжелый исход после инфекции и высокий уровень летальности. Текущие схемы медикаментозной терапии пациентов с постковидным синдромом и сопутствующими заболеваниями носят симптоматический характер. Наиболее частым проявлением постковидного синдрома со  стороны сердечно-сосудистой системы является повышение уровня артериального давления и частоты сердечных сокращений. В связи с этим в настоящем обзоре обсуждаются перспективы применения фиксированной комбинации бисопролола и амлодипина в лечении пациентов с постковидным синдромом, сопровождающимся повышением артериального давления и частоты сердечных сокращений.

The new coronavirus infection COVID-19 from the moment of the first message to the present has spread rapidly in more than two hundred countries around the world, posing a serious threat to the life and health of the population. Most patients who have recovered from COVID-19 continue to complain of shortness of breath, increased fatigue, chest pain, palpitations and other symptoms. Currently, the presence of symptoms 12 weeks after the acute phase of the new coronavirus infection COVID-19 is collectively referred to as post-covid syndrome. Studies have shown that this syndrome occurs frequently in recovered patients with COVID-19, regardless of their age and severity of the disease. This feature significantly distinguishes post-covid syndrome from other syndromes after an infection, and therefore the study of the mechanisms of its development, methods of diagnosis and treatment is an important public health problem. Particular attention is paid to patients with comorbidities, especially those with hypertension and cardiovascular diseases, since they have a more severe outcome after infection and higher case mortality rate. The current drug regimens for patients with post-covid syndrome and concomitant diseases are symptomatic. The most common manifestations of post-covid syndrome from the cardiovascular system are an increase in blood pressure and heart rate. In this regard, this review discusses the prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome, accompanied by an increase in blood pressure and heart rate.

постковидный синдромартериальная гипертензиятахикардиясердечно-сосудистые заболеванияантигипертензивная терапиябисопрололамлодипинpost-covid syndromearterial hypertensiontachycardiacardiovascular diseasesantihypertensive therapybisoprololamlodipineReferencesАвдеев С.Н., Адамян Л.В., Алексеева Е.И., Багненко С.Ф., Баранов А.А., Баранова Н.Н. и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021). М., 2021. 225 с. Режим доступа: https://стопкоронавирус.рф/ai/doc/872/attach/Bmr_COVID-19_compressed.pdf.Avdeev S.N., Adamyan L.V., Alekseeva E.I., Bagnenko S.F., Baranov A.A., Baranova N.N. et al. Interim Guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 11 (07.05.2021). Мoscow; 2021. 225 p. (In Russ.) Available at: https://стопкоронавирус.рф/ai/doc/872/attach/Bmr_COVID-19_compressed.pdf.Del Rio C., Collins L.F., Malani P. Long-Term Health Consequences of COVID-19. JAMA. 2020;324(17):1723–1724. https://doi.org/10.1001/jama.2020.19719.Del Rio C., Collins L.F., Malani P. Long-Term Health Consequences of COVID-19. JAMA. 2020;324(17):1723–1724. https://doi.org/10.1001/jama.2020.19719.Jimeno-Almazán A., Pallarés J.G., Buendía-Romero Á., Martínez-Cava A., Franco-López F., Sánchez-Alcaraz Martínez B.J. et al. Post-COVID-19 Syndrome and the Potential Benefits of Exercise. Int J Environ Res Public Health. 2021;18(10):5329. https://doi.org/10.3390/ijerph18105329.Jimeno-Almazán A., Pallarés J.G., Buendía-Romero Á., Martínez-Cava A., Franco-López F., Sánchez-Alcaraz Martínez B.J. et al. Post-COVID-19 Syndrome and the Potential Benefits of Exercise. Int J Environ Res Public Health. 2021;18(10):5329. https://doi.org/10.3390/ijerph18105329.Sathyamurthy P., Madhavan S., Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. Cureus. 2021;13(8):e17189. https://doi.org/10.7759/cureus.17189.Sathyamurthy P., Madhavan S., Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. Cureus. 2021;13(8):e17189. https://doi.org/10.7759/cureus.17189.Townsend L., Dowds J., O’Brien K., Sheill G., Dyer A.H., O’Kelly B. et al. Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am Thorac Soc. 2021;18(6):997–1003. https://doi.org/10.1513/AnnalsATS.202009-1175OC.Townsend L., Dowds J., O’Brien K., Sheill G., Dyer A.H., O’Kelly B. et al. Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am Thorac Soc. 2021;18(6):997–1003. https://doi.org/10.1513/AnnalsATS.202009-1175OC.Baig A.M. Chronic COVID Syndrome: Need for an Appropriate Medical Terminology for Long-COVID and COVID Long-Haulers. J Med Virol. 2021;93(5):2555–2556. https://doi.org/10.1002/jmv.26624.Baig A.M. Chronic COVID Syndrome: Need for an Appropriate Medical Terminology for Long-COVID and COVID Long-Haulers. J Med Virol. 2021;93(5):2555–2556. https://doi.org/10.1002/jmv.26624.Aghagoli G., Gallo Marin B., Soliman L.B., Sellke F.W. Cardiac Involvement in COVID-19 Patients: Risk Factors, Predictors, and Complications: A Review. J Card Surg. 2020;35(6):1302–1305. https://doi.org/10.1111/jocs.14538.Aghagoli G., Gallo Marin B., Soliman L.B., Sellke F.W. Cardiac Involvement in COVID-19 Patients: Risk Factors, Predictors, and Complications: A Review. J Card Surg. 2020;35(6):1302–1305. https://doi.org/10.1111/jocs.14538.Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K. et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7(11):ofaa507. https://doi.org/10.1093/ofid/ofaa507.Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K. et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7(11):ofaa507. https://doi.org/10.1093/ofid/ofaa507.Van den Borst B., Peters J.B., Brink M., Schoon Y., Bleeker-Rovers C.P., Schers H. et al. Comprehensive Health Assessment Three Months after Recovery from Acute COVID-19. Clin Infect Dis. 2021;73(5):e1089–e1098. https://doi.org/10.1093/cid/ciaa1750.Van den Borst B., Peters J.B., Brink M., Schoon Y., Bleeker-Rovers C.P., Schers H. et al. Comprehensive Health Assessment Three Months after Recovery from Acute COVID-19. Clin Infect Dis. 2021;73(5):e1089–e1098. https://doi.org/10.1093/cid/ciaa1750.Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D. et al. Multiorgan Impairment in Low-Risk Individuals with PostCOVID-19 Syndrome: A Prospective, Community-Based Study. BMJ Open. 2021;11(3):e048391. https://doi.org/10.1136/bmjopen-2020-048391.Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D. et al. Multiorgan Impairment in Low-Risk Individuals with Post-COVID-19 Syndrome: A Prospective, Community-Based Study. BMJ Open. 2021;11(3):e048391. https://doi.org/10.1136/bmjopen-2020-048391.Rajpal S., Tong M.S., Borchers J., Zareba K.M., Obarski T.P., Simonetti O.P., Daniels C.J. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering from COVID-19 Infection. JAMA Cardiol. 2021;6(1):116–118. https://doi.org/10.1001/jamacardio.2020.4916.Rajpal S., Tong M.S., Borchers J., Zareba K.M., Obarski T.P., Simonetti O.P., Daniels C.J. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering from COVID-19 Infection. JAMA Cardiol. 2021;6(1):116–118. https://doi.org/10.1001/jamacardio.2020.4916.Cabrera Martimbianco A.L., Pacheco R.L., Bagattini Â.M., Riera R. Frequency, Signs and Symptoms, and Criteria Adopted for Long COVID-19: A Systematic Review. Int J Clin Pract. 2021;e14357. https://doi.org/10.1111/ijcp.14357.Cabrera Martimbianco A.L., Pacheco R.L., Bagattini Â.M., Riera R. Frequency, Signs and Symptoms, and Criteria Adopted for Long COVID-19: A Systematic Review. Int J Clin Pract. 2021;e14357. https://doi.org/10.1111/ijcp.14357.Johansson M., Ståhlberg M., Runold M., Nygren-Bonnier M., Nilsson J., Olshansky B. et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: the Swedish Experience. JACC Case Rep. 2021;3(4):573–580. https://doi.org/10.1016/j.jaccas.2021.01.009.Johansson M., Ståhlberg M., Runold M., Nygren-Bonnier M., Nilsson J., Olshansky B. et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: the Swedish Experience. JACC Case Rep. 2021;3(4):573–580. https://doi.org/10.1016/j.jaccas.2021.01.009.Lau S.T., Yu W.C., Mok N.S., Tsui P.T., Tong W.L., Cheng S.W. Tachycardia Amongst Subjects Recovering from Severe Acute Respiratory Syndrome (SARS). Int J Cardiol. 2005;100(1):167–169. https://doi.org/10.1016/j.ijcard.2004.06.022.Lau S.T., Yu W.C., Mok N.S., Tsui P.T., Tong W.L., Cheng S.W. Tachycardia Amongst Subjects Recovering from Severe Acute Respiratory Syndrome (SARS). Int J Cardiol. 2005;100(1):167–169. https://doi.org/10.1016/j.ijcard.2004.06.022.Urmeneta Ulloa J., Martínez de Vega V., Salvador Montañés O., Álvarez Vázquez A., Sánchez-Enrique C., Hernández Jiménez S. et al. Cardiac Magnetic Resonance in Recovering COVID-19 Patients. Feature Tracking and Mapping Analysis to Detect Persistent Myocardial Involvement. Int J Cardiol Heart Vasc. 2021;36:100854. https://doi.org/10.1016/j.ijcha.2021.100854.Urmeneta Ulloa J., Martínez de Vega V., Salvador Montañés O., Álvarez Vázquez A., Sánchez-Enrique C., Hernández Jiménez S. et al. Cardiac Magnetic Resonance in Recovering COVID-19 Patients. Feature Tracking and Mapping Analysis to Detect Persistent Myocardial Involvement. Int J Cardiol Heart Vasc. 2021;36:100854. https://doi.org/10.1016/j.ijcha.2021.100854.Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. https://doi.org/10.15829/1560-4071-2020-3-3786.Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial Hypertension in Adults. Clinical Guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786.Муромцева Г.А., Концевая А.В., Константинов В.В., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4–11. https://doi.org/10.15829/1728-8800-2014-6-4-11.Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T.M., Duplyakov D.V. et al. The Prevalence of Non-Infectious Diseases Risk Factors in Russian Population in 2012–2013 Years. The Results of ECVD-RF. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2014;13(6):4–11. (In Russ.) https://doi.org/10.15829/1728-8800-2014-6-4-11.Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A Comprehensive Review of COVID-19 Characteristics. Biol Proced Online. 2020;22:19. https://doi.org/10.1186/s12575-020-00128-2.Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A Comprehensive Review of COVID-19 Characteristics. Biol Proced Online. 2020;22:19. https://doi.org/10.1186/s12575-020-00128-2.Vellas C., Delobel P., de Souto Barreto P., Izopet J. COVID-19, Virology and Geroscience: A Perspective. J Nutr Health Aging. 2020;24(7):685–691. https://doi.org/10.1007/s12603-020-1416-2.Vellas C., Delobel P., de Souto Barreto P., Izopet J. COVID-19, Virology and Geroscience: A Perspective. J Nutr Health Aging. 2020;24(7):685–691. https://doi.org/10.1007/s12603-020-1416-2.Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.Yan F., Huang F., Xu J., Yang P., Qin Y., Lv J. et al. Antihypertensive Drugs Are Associated with Reduced Fatal Outcomes and Improved Clinical Characteristics in Elderly COVID-19 Patients. Cell Discov. 2020;6(1):77. https://doi.org/10.1038/s41421-020-00221-6.Yan F., Huang F., Xu J., Yang P., Qin Y., Lv J. et al. Antihypertensive Drugs Are Associated with Reduced Fatal Outcomes and Improved Clinical Characteristics in Elderly COVID-19 Patients. Cell Discov. 2020;6(1):77. https://doi.org/10.1038/s41421-020-00221-6.Singh S., Offringa-Hup A.K., Logtenberg S., Van der Linden P.D., Janssen W., Klein H. et al. Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2. Hypertension. 2021;78(1):165–173. https://doi.org/10.1161/HYPERTENSIONAHA.121.17328.Singh S., Offringa-Hup A.K., Logtenberg S., Van der Linden P.D., Janssen W., Klein H. et al. Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2. Hypertension. 2021;78(1):165–173. https://doi.org/10.1161/HYPERTENSIONAHA.121.17328.Kjeldsen S.E., Narkiewicz K., Burnier M., Oparil S. Potential Protective Effects of Antihypertensive Treatments during the Covid-19 Pandemic: from Inhibitors of the Renin-Angiotensin System to Beta-Adrenergic Receptor Blockers. Blood Press. 2021;30(1):1–3. https://doi.org/10.1080/08037051.2021.1862483.Kjeldsen S.E., Narkiewicz K., Burnier M., Oparil S. Potential Protective Effects of Antihypertensive Treatments during the Covid-19 Pandemic: from Inhibitors of the Renin-Angiotensin System to Beta-Adrenergic Receptor Blockers. Blood Press. 2021;30(1):1–3. https://doi.org/10.1080/08037051.2021.1862483.Oliver E., Mayor F. Jr, D’Ocon P. Beta-Blockers: Historical Perspective and Mechanisms of Action. Rev Esp Cardiol (Engl Ed). 2019;72(10):853–862. https://doi.org/10.1016/j.rec.2019.04.006.Oliver E., Mayor F. Jr, D’Ocon P. Beta-Blockers: Historical Perspective and Mechanisms of Action. Rev Esp Cardiol (Engl Ed). 2019;72(10):853–862. https://doi.org/10.1016/j.rec.2019.04.006.Недогода С.В. Фиксированная комбинация бисопролола и амлодипина: новые возможности антигипертензивной терапии. Фарматека. 2013;(6): 90–97. Режим доступа: https://pharmateca.ru/ru/archive/article/11659.Nedogoda S.V. Fixed Combination of Bisoprolol and Amlodipine: New Potentials for Antihypertensive Therapy. Farmateka. 2013;(6):90–97. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/11659.Palatini P. Role of Elevated Heart Rate in the Development of Cardiovascular Disease in Hypertension. Hypertension. 2011;58(5):745– 750. https://doi.org/10.1161/HYPERTENSIONAHA.111.173104.Palatini P. Role of Elevated Heart Rate in the Development of Cardiovascular Disease in Hypertension. Hypertension. 2011;58(5):745–750. https://doi.org/10.1161/HYPERTENSIONAHA.111.173104.Julius S., Palatini P., Kjeldsen S.E., Zanchetti A., Weber M.A., McInnes G.T. et al. Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients with High-Risk Systemic Hypertension. Am J Cardiol. 2012;109(5):685–692. https://doi.org/10.1016/j.amjcard.2011.10.025.Julius S., Palatini P., Kjeldsen S.E., Zanchetti A., Weber M.A., McInnes G.T. et al. Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients with High-Risk Systemic Hypertension. Am J Cardiol. 2012;109(5):685–692. https://doi.org/10.1016/j.amjcard.2011.10.025.King D.E., Everett C.J., Mainous A.G., Liszka H.A. Long-Term Prognostic Value of Resting Heart Rate in Subjects with Prehypertension. Am J Hypertens. 2006;19(8):796–800. https://doi.org/10.1016/j.amjhyper.2006.01.019.King D.E., Everett C.J., Mainous A.G., Liszka H.A. Long-Term Prognostic Value of Resting Heart Rate in Subjects with Prehypertension. Am J Hypertens. 2006;19(8):796–800. https://doi.org/10.1016/j.amjhyper.2006.01.019.Wong G.W., Boyda H.N., Wright J.M. Blood Pressure Lowering Efficacy of Beta-1 Selective Beta Blockers for Primary Hypertension. Cochrane Database Syst Rev. 2016;3(3):CD007451. https://doi.org/10.1002/14651858.CD007451.pub2.Wong G.W., Boyda H.N., Wright J.M. Blood Pressure Lowering Efficacy of Beta-1 Selective Beta Blockers for Primary Hypertension. Cochrane Database Syst Rev. 2016;3(3):CD007451. https://doi.org/10.1002/14651858.CD007451.pub2.Gao P., Wu W., Tian R., Yan X., Qian H., Guo F. et al. Association between Tachyarrhythmia and Mortality in a Cohort of Critically Ill Patients with Coronavirus Disease 2019 (COVID-19). Ann Transl Med. 2021;9(10):883. https://doi.org/10.21037/atm-21-2282.Gao P., Wu W., Tian R., Yan X., Qian H., Guo F. et al. Association between Tachyarrhythmia and Mortality in a Cohort of Critically Ill Patients with Coronavirus Disease 2019 (COVID-19). Ann Transl Med. 2021;9(10):883. https://doi.org/10.21037/atm-21-2282.Бойцов С.А., Карпов Ю.А., Остроумова О.Д., Агеев Ф.Т., Кисляк О.А., Стрюк Р.И. и др. Роль активации симпатической нервной системы в лечении артериальной гипертонии. Фокус на пациента с повышенной частотой сердечных сокращений. Экспертное мнение. Атмосфера. Новости кардиологии. 2020;(1):20–28. https://doi.org/10.24411/2076-4189-2020-11047.Boytsov S.A., Karpov Yu.A., Ostroumova O.D., Ageev F.T., Kislyak O.A., Stryuk R.I. et al. The Role of Activation of the Sympathetic Nervous System in the Treatment of Arterial Hypertension. Focus on a Patient with an Increased Heart Rate. Expert Opinion. Atmosfera. Novosti kardiologii = Atmosphere. Cardiology News. 2020;(1):20–28. (In Russ.) https://doi.org/10.24411/2076-4189-2020-11047.Войцеховский Д., Пападеметрио В. Бета-адреноблокаторы в лечении артериальной гипертензии: акцент на небиволол. Российский кардиологический журнал. 2008;(4):43–52. Режим доступа: https://russjcardiol.elpub.ru/jour/article/view/1585?locale=ru_RU.Voytsekhovsky D., Papademetrio V. Beta-Adrenoblockers in Arterial Hypertension Treatment: Focus on Nebivolol. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2008;(4):43–52. (In Russ.) Available at: https://russjcardiol.elpub.ru/jour/article/view/1585?locale=ru_RU.Barron A.J., Zaman N., Cole G.D., Wensel R., Okonko D.O., Francis D.P. Systematic Review of Genuine versus Spurious Side-Effects of BetaBlockers in Heart Failure Using Placebo Control: Recommendations for Patient Information. Int J Cardiol. 2013;168(4):3572–3579. https://doi.org/10.1016/j.ijcard.2013.05.068.Barron A.J., Zaman N., Cole G.D., Wensel R., Okonko D.O., Francis D.P. Systematic Review of Genuine versus Spurious Side-Effects of Beta Blockers in Heart Failure Using Placebo Control: Recommendations for Patient Information. Int J Cardiol. 2013;168(4):3572–3579. https://doi.org/10.1016/j.ijcard.2013.05.068.Огарков М.Ю., Баранова М.Н., Скрипченко А.Е. Практические аспекты применения фиксированных комбинаций в лечении артериальной гипертензии. Системные гипертензии. 2014;11(1):22–25. https://doi.org/10.26442/SG29002.Ogarkov M.Y., Baranova M.N., Skripchenko A.E. Practical Aspects of Fixed Combinations in the Treatment of Hypertension. Sistemnyye gipertenzii = Systemic Hypertension. 2014;11(1):22–25. (In Russ.) https://doi.org/10.26442/SG29002.Yang T., Jiang Y., Hao Y., Zhou S., Xu X., Qu B. et al. Comparison of Bisoprolol to a Metoprolol CR/ZOK Tablet for Control of Heart Rate and Blood Pressure in Mild-to-Moderate Hypertensive Patients: the CREATIVE Study. Hypertens Res. 2017;40(1):79–86. https://doi.org/10.1038/hr.2016.101.Yang T., Jiang Y., Hao Y., Zhou S., Xu X., Qu B. et al. Comparison of Bisoprolol to a Metoprolol CR/ZOK Tablet for Control of Heart Rate and Blood Pressure in Mild-to-Moderate Hypertensive Patients: the CREATIVE Study. Hypertens Res. 2017;40(1):79–86. https://doi.org/10.1038/hr.2016.101.Haasis R., Bethge H. Exercise Blood Pressure and Heart Rate Reduction 24 and 3 Hours after Drug Intake in Hypertensive Patients Following 4 Weeks of Treatment with Bisoprolol and Metoprolol: A Randomized Multicentre Double-Blind Study (BISOMET). Eur Heart J. 1987;8(Suppl M):103–113. https://doi.org/10.1093/eurheartj/8.suppl_m.103.Haasis R., Bethge H. Exercise Blood Pressure and Heart Rate Reduction 24 and 3 Hours after Drug Intake in Hypertensive Patients Following 4 Weeks of Treatment with Bisoprolol and Metoprolol: A Randomized Multicentre Double-Blind Study (BISOMET). Eur Heart J. 1987;8(Suppl M): 103–113. https://doi.org/10.1093/eurheartj/8.suppl_m.103.De Muinck E.D., Buchner-Moell D., van de Ven L.L., Lie K.I. Comparison of the Safety and Efficacy of Bisoprolol versus Atenolol in Stable Exercise-Induced Angina Pectoris: A Multicenter International Randomized Study of Angina Pectoris (MIRSA). J Cardiovasc Pharmacol. 1992;19(6):870–875. https://doi.org/10.1097/00005344-199206000-00005.De Muinck E.D., Buchner-Moell D., van de Ven L.L., Lie K.I. Comparison of the Safety and Efficacy of Bisoprolol versus Atenolol in Stable ExerciseInduced Angina Pectoris: A Multicenter International Randomized Study of Angina Pectoris (MIRSA). J Cardiovasc Pharmacol. 1992;19(6):870–875. https://doi.org/10.1097/00005344-199206000-00005.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial. Lancet. 1999;353(9146):9–13. https://doi.org/10.1016/S0140-6736(98)11181-9.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial. Lancet. 1999;353(9146):9–13. https://doi.org/10.1016/S0140-6736(98)11181-9.Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J. et al. Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis. Lancet. 2016;387(10022): 957–967. https://doi.org/10.1016/S0140-6736(15)01225-8.Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J. et al. Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis. Lancet. 2016;387(10022): 957–967. https://doi.org/10.1016/S0140-6736(15)01225-8.Thomopoulos C., Parati G., Zanchetti A. Effects of Blood Pressure Lowering on Outcome Incidence in Hypertension: 4. Effects of Various Classes of Antihypertensive Drugs – Overview and Meta-Analyses. J Hypertens. 2015;33(2):195–211. https://doi.org/10.1097/HJH.0000000000000447.Thomopoulos C., Parati G., Zanchetti A. Effects of Blood Pressure Lowering on Outcome Incidence in Hypertension: 4. Effects of Various Classes of Antihypertensive Drugs – Overview and Meta-Analyses. J Hypertens. 2015;33(2):195–211. https://doi.org/10.1097/HJH.0000000000000447.Goldsmith S.R. Effect of Amlodipine and Felodipine on Sympathetic Activity and Baroreflex Function in Normal Humans. Am J Hypertens. 1995;8(9):902–928. https://doi.org/10.1016/0895-7061(95)00163-J.Goldsmith S.R. Effect of Amlodipine and Felodipine on Sympathetic Activity and Baroreflex Function in Normal Humans. Am J Hypertens. 1995;8(9):902–928. https://doi.org/10.1016/0895-7061(95)00163-J.Peng C., Wang H., Guo Y.F., Qi G.Y., Zhang C.X., Chen T. et al. Calcium Channel Blockers Improve Prognosis of Patients with Coronavirus Disease 2019 and Hypertension. Chin Med J (Engl). 2021;134(13):1602–1609. https://doi.org/10.1097/CM9.0000000000001479.Peng C., Wang H., Guo Y.F., Qi G.Y., Zhang C.X., Chen T. et al. Calcium Channel Blockers Improve Prognosis of Patients with Coronavirus Disease 2019 and Hypertension. Chin Med J (Engl). 2021;134(13):1602–1609. https://doi.org/10.1097/CM9.0000000000001479.Haria M., Wagstaff A.J. Amlodipine. A Reappraisal of Its Pharmacological Properties and Therapeutic Use in Cardiovascular Disease. Drugs. 1995;50(3):560–586. https://doi.org/10.2165/00003495-199550030-00009.Haria M., Wagstaff A.J. Amlodipine. A Reappraisal of Its Pharmacological Properties and Therapeutic Use in Cardiovascular Disease. Drugs. 1995;50(3):560–586. https://doi.org/10.2165/00003495-199550030-00009.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997. https://doi.org/10.1001/jama.288.23.2981.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997. https://doi.org/10.1001/jama.288.23.2981.Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M. et al. Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. Lancet. 2005;366(9489):895–906. https://doi.org/10.1016/S0140-6736(05)67185-1.Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M. et al. Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. Lancet. 2005;366(9489):895–906. https://doi.org/10.1016/S0140-6736(05)67185-1.Jamerson K., Weber M.A., Bakris G.L., Dahlöf B., Pitt B., Shi V. et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008;359(23):2417–2428. https://doi.org/10.1056/NEJMoa0806182.Jamerson K., Weber M.A., Bakris G.L., Dahlöf B., Pitt B., Shi V. et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med. 2008;359(23):2417–2428. https://doi.org/10.1056/NEJMoa0806182.Hernández R.H., Armas-Hernández M.J., Velasco M., Israili Z.H., ArmasPadilla M.C. Calcium Antagonists and Atherosclerosis Protection in Hypertension. Am J Ther. 2003;10(6):409–414. https://doi.org/10.1097/00045391-200311000-00006.Hernández R.H., Armas-Hernández M.J., Velasco M., Israili Z.H., ArmasPadilla M.C. Calcium Antagonists and Atherosclerosis Protection in Hypertension. Am J Ther. 2003;10(6):409–414. https://doi.org/10.1097/00045391-200311000-00006.Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D. et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and Normal Blood Pressure: the CAMELOT Study: A Randomized Controlled Trial. JAMA. 2004;292(18):2217–2225. https://doi.org/10.1001/jama.292.18.2217.Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D. et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and Normal Blood Pressure: the CAMELOT Study: A Randomized Controlled Trial. JAMA. 2004;292(18):2217–2225. https://doi.org/10.1001/jama.292.18.2217.Straus M.R., Bidon M., Tang T., Whittaker G.R., Daniel S. FDA approved Calcium Channel Blockers Inhibit SARS-CoV-2 Infectivity in Epithelial Lung Cells. bioRxiv. 2020;2020.07.21.214577. https://doi.org/10.1101/2020.07.21.214577.Straus M.R., Bidon M., Tang T., Whittaker G.R., Daniel S. FDA approved Calcium Channel Blockers Inhibit SARS-CoV-2 Infectivity in Epithelial Lung Cells. bioRxiv. 2020;2020.07.21.214577. https://doi.org/10.1101/2020.07.21.214577.Garjón J., Saiz L.C., Azparren A., Elizondo J.J., Gaminde I., Ariz M.J., Erviti J. First-Line Combination Therapy versus First-Line Monotherapy for Primary Hypertension. Cochrane Database Syst Rev. 2017;1(1):CD010316. https://doi.org/10.1002/14651858.CD010316.pub2.Garjón J., Saiz L.C., Azparren A., Elizondo J.J., Gaminde I., Ariz M.J., Erviti J. First-Line Combination Therapy versus First-Line Monotherapy for Primary Hypertension. Cochrane Database Syst Rev. 2017;1(1):CD010316. https://doi.org/10.1002/14651858.CD010316.pub2.Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination Therapy versus Monotherapy in Reducing Blood Pressure: Meta-Analysis on 11,000 Participants from 42 Trials. Am J Med. 2009;122(3):290–300. https://doi.org/10.1016/j.amjmed.2008.09.038.Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination Therapy versus Monotherapy in Reducing Blood Pressure: Meta-Analysis on 11,000 Participants from 42 Trials. Am J Med. 2009;122(3):290–300. https://doi.org/10.1016/j.amjmed.2008.09.038.Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F. et al. Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study. Lancet. 2004;364(9438):937–952. https://doi.org/10.1016/S0140-6736(04)17018-9.Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F. et al. Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study. Lancet. 2004;364(9438):937–952. https://doi.org/10.1016/S0140-6736(04)17018-9.Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S. et al. Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1·25 Million People. Lancet. 2014;383(9932):1899–1911. https://doi.org/10.1016/S0140-6736(14)60685-1.Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D.,Gottwald-Hostalek U., Li L., Montenegro P. Bisoprolol/Amlodipine Combination Therapy Improves Blood Pressure Control in Patients with Essential Hypertension Following Monotherapy Failure. Curr Med Res Opin. 2016;32(10):1735–1743. https://doi.org/10.1080/03007995.2016.1205573.Denaxas S. et al. Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1·25 Million People. Lancet. 2014;383(9932):1899–1911. https://doi.org/10.1016/S0140-6736(14)60685-1.Чесникова А.И., Сафроненко В.А., Коломацкая О.Е. Оценка эффективности фиксированной комбинации бисопролола и амлодипина в амбулаторном лечении больных артериальной гипертензией и ишемической болезнью сердца. Кардиология. 2014;54(9):17–23. Режим доступа: http://www.gipertonik.ru/files/conference/kongress-17-mart-18-mart-2021/virtual_exhibition/merck/article_4.pdf.Gottwald-Hostalek U., Li L., Montenegro P. Bisoprolol/Amlodipine Combination Therapy Improves Blood Pressure Control in Patients with Essential Hypertension Following Monotherapy Failure. Curr Med Res Opin. 2016;32(10):1735–1743. https://doi.org/10.1080/03007995.2016.1205573.Williams B., Lacy P.S. Impact of Heart Rate on Central Aortic Pressures and Hemodynamics: Analysis from the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54(8):705–713. https://doi.org/10.1016/j.jacc.2009.02.088.Chesnikova A.I., Safronenko V.A., Kolomakskaya O.E. Evaluating the Effectiveness of a Fixed Combination of Amlodipine and Bisoprolol in Ambulatory Patients With Arterial Hypertension and Ischemic Heart Disease. Kardiologiya. 2014;54(9):17–23. (In Russ.) Available at: http://www.gipertonik.ru/files/conference/kongress-17-mart-18-mart-2021/virtual_ exhibition/merck/article_4.pdf.Кобалава Ж.Д., Котовская Ю.В., Богомаз А.В. Фиксированная комбинация бисопролола и амлодипина нивелирует влияние β-адреноблокатора на показатели центральной пульсовой волны у больных артериальной гипертонией. Кардиология. 2015;55(12):11–16. Режим доступа: http://www.gipertonik.ru/files/conference/kongress-17-mart-18-mart-2021/virtual_exhibition/merck/article_5.pdf.Williams B., Lacy P.S. Impact of Heart Rate on Central Aortic Pressures and Hemodynamics: Analysis from the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54(8):705–713. https://doi.org/10.1016/j.jacc.2009.02.088.Murdoch D., Heel R.C. Amlodipine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease. Drugs. 1991;41(3):478–505. https://doi.org/10.2165/00003495-199141030-00009.Kobalava Zh.D., Kotovskaya Yu.V., Bogomaz A.V. The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of β-Blockers on Central Pulse Wave in Patients With Arterial Hypertension. Kardiologiya. 2015;55(12):11–16. (In Russ.) Available at: http://www.gipertonik.ru/files/conference/kongress-17-mart-18-mart-2021/virtual_exhibition/merck/article_5.pdf.Vasanthakumar N. Can Beta-Adrenergic Blockers Be Used in the Treatment of COVID-19? Med Hypotheses. 2020;142:109809. https://doi.org/10.1016/j.mehy.2020.109809.Murdoch D., Heel R.C. Amlodipine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Cardiovascular Disease. Drugs. 1991;41(3):478–505. https://doi.org/10.2165/00003495-199141030-00009.Grassi G. Sympathetic Overdrive in Hypertension: Clinical and Therapeutic Relevance. The e-journal of the ESC Council for Cardiology Practice. 2015;13(36). Available at: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/sympathetic-overdrive-in-hypertension-clinical-and-therapeuticrelevance.Vasanthakumar N. Can Beta-Adrenergic Blockers Be Used in the Treatment of COVID-19? Med Hypotheses. 2020;142:109809. https://doi.org/10.1016/j.mehy.2020.109809.Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S. et al. Beta-Adrenergic Receptor Blockade as a Therapeutic Approach for Suppressing the Renin-Angiotensin-Aldosterone System in Normotensive and Hypertensive Subjects. Am J Hypertens. 1999;12(5):451–459. https://doi.org/10.1016/s0895-7061(99)00005-9.Grassi G. Sympathetic Overdrive in Hypertension: Clinical and Therapeutic Relevance. The e-journal of the ESC Council for Cardiology Practice. 2015;13(36). Available at: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/sympathetic-overdrive-in-hypertension-clinical-and-therapeuticrelevance.Kirsten R., Neff J., Heintz B., Nemeth N., Rahlfs V.W., Nelson K. Influence of Different Bisoprolol Doses on Hemodynamics, Plasma Catecholamines, Platelet Aggregation, and Alpha 2- and Beta-Receptors in Hypertensive Patients. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S113–S121. https://doi.org/10.1097/00005344-198511001-00021.Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S. et al. Beta-Adrenergic Receptor Blockade as a Therapeutic Approach for Suppressing the Renin-Angiotensin-Aldosterone System in Normotensive and Hypertensive Subjects. Am J Hypertens. 1999;12(5):451–459. https://doi.org/10.1016/s0895-7061(99)00005-9.Prager G., Prager W., Hönig B. Effect of Beta-Adrenergic Blockade on the Circadian Rhythm of Myocardial Ischemia in Ambulatory Patients with Stable Angina. J Cardiovasc Pharmacol. 1989;13(4):638–643. Available at: https://pubmed.ncbi.nlm.nih.gov/2471003/.Kirsten R., Neff J., Heintz B., Nemeth N., Rahlfs V.W., Nelson K. Influence of Different Bisoprolol Doses on Hemodynamics, Plasma Catecholamines, Platelet Aggregation, and Alpha 2- and Beta-Receptors in Hypertensive Patients. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S113–S121. https://doi.org/10.1097/00005344-198511001-00021.Pinto-Sietsma S.J., Flossdorf M., Buchholz V.R., Offerhaus J., Bleijendaal H., Beudel M. et al. Antihypertensive Drugs in COVID-19 Infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):415–416. https://doi.org/10.1093/ehjcvp/pvaa058.Prager G., Prager W., Hönig B. Effect of Beta-Adrenergic Blockade on the Circadian Rhythm of Myocardial Ischemia in Ambulatory Patients with Stable Angina. J Cardiovasc Pharmacol. 1989;13(4):638–643. Available at: https://pubmed.ncbi.nlm.nih.gov/2471003/.Koh K.K., Han S.H., Ahn J.Y., Chung W.J., Lee Y., Shin E.K. Amlodipine Improves Endothelial Function and Metabolic Parameters in Patients with Hypertension. Int J Cardiol. 2009;133(1):23–31. https://doi.org/10.1016/j.ijcard.2007.11.058.Pinto-Sietsma S.J., Flossdorf M., Buchholz V.R., Offerhaus J., Bleijendaal H., Beudel M. et al. Antihypertensive Drugs in COVID-19 Infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):415–416. https://doi.org/10.1093/ehjcvp/pvaa058.Zhang L.K., Sun Y., Zeng H., Wang Q., Jiang X., Shang W.J. et al. Calcium channel Blocker Amlodipine Besylate Therapy Is Associated with Reduced Case Fatality Rate of COVID-19 Patients with Hypertension. Cell Discov. 2020;6(1):96. https://doi.org/10.1038/s41421-020-00235-0.Koh K.K., Han S.H., Ahn J.Y., Chung W.J., Lee Y., Shin E.K. Amlodipine Improves Endothelial Function and Metabolic Parameters in Patients with Hypertension. Int J Cardiol. 2009;133(1):23–31. https://doi.org/10.1016/j.ijcard.2007.11.058.Запесочная И.Л., Автандилов А.Г. Динамика показателей церебрального кровотока при комбинированной терапии амлодипином и бисопрололом. Клиническая медицина. 2016;94(9):908–914. https://doi.org/10.18821/0023-2149-2016-94-12-908-914. 68. Недогода С.В., Саласюк А.С., Цома В.В., Чумачек Е.В. Влияние фиксированной комбинации амлодипина и бисопролола на сосудистую эластичность у пациентов с артериальной гипертензией. Consilium Medicum. 2015;17(10):19–22. https://doi.org/10.26442/2075-1753_2015.10.19-22.Zhang L.K., Sun Y., Zeng H., Wang Q., Jiang X., Shang W.J. et al. Calcium channel Blocker Amlodipine Besylate Therapy Is Associated with Reduced Case Fatality Rate of COVID-19 Patients with Hypertension. Cell Discov. 2020;6(1):96. https://doi.org/10.1038/s41421-020-00235-0.Скибицкий В.В., Пыхалова Н.Е., Фендрикова А.В. Структурнофункциональные особенности миокарда левого желудочка у женщин с артериальной гипертонией и метаболическим синдромом на фоне гипотиреоза. Кубанский научный медицинский вестник. 2011;3(126):152–158. Режим доступа: https://www.elibrary.ru/item.asp?id=16905435.Zapesochnaya I.L., Avtandilov A.G. Dynamics of Characteristics of Cerebral Circulation during Combined Treatment with Amlodipine and Bisoprolol. Klinicheskaya meditsina = Clinical Medicine. 2016;94(9):908–914. (In Russ.) https://doi.org/10.18821/0023-2149-2016-94-12-908-914.Карпов Ю.А., Деев А.Д. Неконтролируемая артериальная гипертония – новые возможности в решении проблемы повышения эффективности лечения. Кардиология. 2012;52(2):29–35. Режим доступа: https://medi.ru/info/7675/.Nedogoda S.V., Salasiuk A.S., Tsoma V.V., Chumachek E.V. The Influence of FixedDose Combination of Amlodipine and Bisoprolol on Vascular Elasticity in Patients with Arterial Hypertension. Consilium Medicum. 2015;17(10):19–22. (In Russ.) https://doi.org/10.26442/2075-1753_2015.10.19-22.Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., Schwartz J.S. Predictors of Adherence with Antihypertensive and Lipid-Lowering Therapy. Arch Intern Med. 2005;165(10):1147–1152. https://doi.org/10.1001/archinte.165.10.1147.Skibitskiy V.V., Pykhalova N.E., Fendrikova A.V. Structural and Functional Features of the Left Ventricular Myocardium in Women with Arterial Hypertension and Metabolic Syndrome against the Background of Hypothyroidism. Kubanskiy nauchnyy meditsinskiy vestnik = Kuban Scientific Medical Bulletin. 2011;3(126):152–158. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=16905435.Czarnecka D., Koch E.M., Gottwald-Hostalek U. Benefits of a Fixed-Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension in Daily Practice: Results of More Than 4000 Patients. Curr Med Res Opin. 2015;31(5):875–881. https://doi.org/10.1185/03007995.2015.1027676.Karpov Yu.A., Deev A.D. Uncontrolled Arterial Hypertension – New Possibilities in Solving Problems of Increasing the Effectiveness of Treatment. Kardiologiya. 2012;52(2):29–35. (In Russ.) Available at: https://medi.ru/info/7675/Hostalek U., Czarnecka D., Koch E.M. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther. 2015;4(2):179–190. https://doi.org/10.1007/s40119-015-0045-z.Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., Schwartz J.S. Predictors of Adherence with Antihypertensive and LipidLowering Therapy. Arch Intern Med. 2005;165(10):1147–1152. https://doi.org/10.1001/archinte.165.10.1147.Тарловская Е.И., Скибицкий В.В., Мальчикова С.В., Фендрикова А.В., Скибицкий А.В., Сиротенко Д.В. Фармакоэкономическая эффективность фиксированной комбинации бисопролола и амлодипина. Кардиология. 2015;55(4);25–29. Режим доступа: https://www.elibrary.ru/item.asp?id=23644338.Czarnecka D., Koch E.M., Gottwald-Hostalek U. Benefits of a Fixed-Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension in Daily Practice: Results of More Than 4000 Patients. Curr Med Res Opin. 2015;31(5):875–881. https://doi.org/10.1185/03007995.2015.1027676.Hostalek U., Czarnecka D., Koch E.M. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther. 2015;4(2):179–190. https://doi.org/10.1007/s40119-015-0045-z.Hostalek U., Czarnecka D., Koch E.M. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther. 2015;4(2):179–190. https://doi.org/10.1007/s40119-015-0045-z.Tarlovskaya E.I., Skibitsky V.V., Malchikova S.V., Fendrikova A.V., Skibitsky A.V., Sirotenko D.V. Pharmacoeconomic Effectiveness of a Fixed Combination of Bisoprolol and Amlodipine. Kardiologiya. 2015;55(4);25–29. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=23644338.Tarlovskaya E.I., Skibitsky V.V., Malchikova S.V., Fendrikova A.V., Skibitsky A.V., Sirotenko D.V. Pharmacoeconomic Effectiveness of a Fixed Combination of Bisoprolol and Amlodipine. Kardiologiya. 2015;55(4);25–29. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=23644338.

The authors declare that there are no conflicts of interest present.